NDA 215904 · Immedica Pharma
Ztalmy
Ganaxolone · Oral · Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
NovelPriority reviewOrphanCDER novel approval, Mar 18, 2022: To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder
Last checked: Nov 19, 2026Latest source record: Oct 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Mar 18, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
25
8 Phase 3, 0 recruiting
FAERS reports
670
350 serious, 16 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 4, 2026.
ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ZTALMY is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ( 1 )
Mechanism: The precise mechanism by which ganaxolone exerts its therapeutic effects in the treatment of seizures associated with CDD is unknown, but its anticonvulsant effects are thought to result from positive allosteric modulation of the gamma-aminobutyric acid type A (GABA A ) receptor in the CNS.
Therapeutic areas: Neurology · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 16, 2025 Supplement 11 · Efficacy OrphanLetterLabel
- Mar 18, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- ZTALMY · GANAXOLONE 50MG/ML · SUSPENSION, ORAL · Prescription · TE TBD
Clinical trials
Interventional ClinicalTrials.gov studies with "Ganaxolone" as an intervention, any sponsor and status, largest first.
- Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label ExtensionPivotal-lookingCompleted
Marinus PharmaceuticalsIndustry
NCT01963208 · 405 participants · Start Oct 2013 · Primary completion May 2016
Drug: ganaxolone; Placebo · For: Drug Resistant Partial Onset Seizure
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City, Arizona · 71 sites in all
- A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset SeizuresPivotal-lookingCompleted
Marinus PharmaceuticalsIndustry
NCT00465517 · 147 participants · Start Feb 2007 · Primary completion Oct 2008
Drug: Ganaxolone · For: Partial Epilepsy; Catamenial Epilepsy
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 27 sites in all
- Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyPivotal-lookingCompleted
Marinus PharmaceuticalsIndustry
NCT05323734 · 129 participants · Start Apr 1, 2022 · Primary completion Sep 9, 2024
Drug: Ganaxolone; Placebo · For: Tuberous Sclerosis Complex
Sites: Little Rock, Arkansas; Los Angeles, California; Orange, California · 63 sites in all
Marinus PharmaceuticalsIndustry
NCT00512317 · 123 participants · Start Jun 2007 · Primary completion Dec 2009
Drug: ganaxolone · For: Epilepsies, Partial
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 25 sites in all
- Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related EpilepsyPivotal-lookingTerminated
Marinus PharmaceuticalsIndustry
NCT05604170 · 117 participants · Start May 16, 2022 · Primary completion Apr 2, 2025
Drug: Ganaxolone · For: Tuberous Sclerosis Complex
Sites: Little Rock, Arkansas; Los Angeles, California; Orange, California · 54 sites in all
- Ganaxolone in Posttraumatic Stress Disorder (PTSD)Pivotal-lookingCompleted
Marinus PharmaceuticalsIndustry
NCT01339689 · 112 participants · Start Apr 2011 · Primary completion Jan 2014
Drug: Ganaxolone; Placebo · For: PTSD
Sites: San Diego, California; Washington D.C., District of Columbia; Boston, Massachusetts · 8 sites in all
- Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency DisorderPivotal-lookingCompleted
Marinus PharmaceuticalsIndustry
NCT03572933 · 101 participants · Start Jun 30, 2018 · Primary completion Jul 31, 2020
Drug: ganaxolone; Placebo · For: CDKL5 Deficiency Disorder
Sites: Phoenix, Arizona; Los Angeles, California; Aurora, Colorado · 36 sites in all
- Randomized Therapy In Status EpilepticusPivotal-lookingCompleted
Marinus PharmaceuticalsIndustry
NCT04391569 · 100 participants · Start Dec 9, 2020 · Primary completion Mar 30, 2024
Drug: Ganaxolone; Placebo · For: Status Epilepticus
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 74 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure204
- product dose omission issue101
- drug ineffective88
- somnolence58
- change in seizure presentation43
- pneumonia31
- off label use28
- vomiting24
- fatigue15
- illness15
- weight decreased15
- pyrexia12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 24 |
| 2023 | 109 |
| 2024 | 197 |
| 2025 | 279 |
| 2026 | 59 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ztalmy (Ganaxolone)
2024 spending
$2.0M
Beneficiaries
12
101 claims
Per beneficiary
$162,989
$24.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $952,925 |
| 2024 | $1,955,865 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Neurosteroids and Seizure Activity.
Miziak B, Chrościska-Krawczyk M, Czuczwar SJ · Front Endocrinol (Lausanne) 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
Knight EMP, Amin S, Bahi-Buisson N, et al. · Lancet Neurol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Tough to treat: What we know about managing PCDH19-related epilepsy - Systematic review.
Tobiasz A, Hager M, Dwbowska J, et al. · Seizure 2025 · Systematic Review
- A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy.
Khan P, Saini S, Hussain S, et al. · Expert Opin Pharmacother 2024 · Systematic Review, Meta-Analysis
- Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial.
Downs J, Jacoby P, Specchio N, et al. · Eur J Paediatr Neurol 2024 · Clinical Trial, Phase III, Multicenter Study
- Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.
Olson HE, Amin S, Bahi-Buisson N, et al. · Epilepsia 2024 · Randomized Controlled Trial
Sponsor: Immedica Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.